- 米国企業
- PTC THERAPEUTICS, INC.
PTC THERAPEUTICS, INC.PTCT
時価総額
$25.4億
PER
| 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
| Net product revenue | - | - | - | - | - | - | - | 333 | 429 | 535 | 661 |
| Collaboration revenue | - | - | - | - | - | - | - | 43 | 55 | 50 | - |
| Collaboration revenue | - | - | - | - | - | - | - | - | - | - | 100 |
| Royalty revenue | - | - | - | - | - | - | - | 5 | 55 | 114 | 169 |
| Manufacturing revenue | - | - | - | - | - | - | - | - | - | - | 8 |
| Revenue | 35 | 25 | 37 | 83 | 194 | 265 | 307 | 381 | 539 | 699 | 938 |
| Cost of Goods and Service, Excluding Amortization Of Intangible Assets | - | - | - | - | - | - | - | 19 | 32 | 45 | 65 |
| Amortization of intangible assets | - | - | - | - | 15 | 23 | 28 | 37 | 55 | 117 | 223 |
| Research and development | 55 | 80 | 122 | 118 | 117 | 172 | 257 | 478 | 541 | 651 | 667 |
| Selling, general and administrative | - | - | - | - | - | 154 | 203 | 245 | 286 | 326 | 333 |
| Change in the fair value of contingent consideration | - | - | - | - | - | -19 | -48 | -23 | 1 | 26 | 128 |
| Intangible asset impairment | - | - | - | - | - | - | - | - | - | 33 | 218 |
| Settlement of deferred and contingent consideration | - | - | - | - | - | - | - | 11 | - | - | - |
| Total operating expenses | 80 | 125 | 204 | 215 | 259 | 380 | 548 | 813 | 913 | 1,146 | 1,377 |
| Total operating expenses | 80 | 125 | 204 | 215 | 259 | 380 | 548 | 813 | 913 | 1,146 | 1,377 |
| Loss from operations | -45,397,469 | -99 | -167 | -132 | -64 | -116 | -241 | -432 | -374 | -447 | -440 |
| Interest expense, net | -6,083,655 | 1 | -2 | -8 | -12 | -13 | -12 | -56 | -86 | -91 | -129 |
| Other income (expense), net | 37,512 | -0 | -0 | -1 | -1 | 0 | 14 | 85 | -58 | -49 | 10 |
| Loss before income tax benefit (expense) | -51,573,575 | -98 | -170 | -142 | -78 | -128 | -240 | -403 | -518 | -587 | -696 |
| Loss on extinguishment of debt | -129,963 | - | - | - | - | - | - | - | - | - | -138 |
| Income tax benefit (expense) | - | -5 | 0 | 1 | 1 | -0 | 12 | 35 | 6 | -28 | -70 |
| Loss before income tax benefit (expense) | -51,573,575 | -98 | -170 | -142 | -78 | -128 | -240 | -403 | -518 | -587 | -696 |
| Net loss attributable to common stockholders | -51,573,575 | -94 | -170 | -142 | -79 | -128 | -252 | -438 | -524 | -559 | -627 |
| Income tax benefit (expense) | - | -5 | 0 | 1 | 1 | -0 | 12 | 35 | 6 | -28 | -70 |
| Net loss attributable to common stockholders | -51,573,575 | -94 | -170 | -142 | -79 | -128 | -252 | -438 | -524 | -559 | -627 |
| Basic | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 |
| Diluted | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 |
| Basic | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 |
| Diluted | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 |